Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma

  • 10 Accesses


BALB/c mice were immunized with the syngeneic 3-methylcholanthrene-induced fibrosarcoma CA-2 by the growth and excision method. When lymphoid cells from different organs of these tumor-free mice were tested in a direct 51Cr-release assay, peritoneal exudate cells but not spleen cells displayed specific cytotoxicity against the syngeneic tumor target. A cytotoxic response could be obtained by tumor-immune spleen cells when cultured in a mixed lymphocyte tumor cell culture (MLTC) at high but not low density although at the same effector/stimulator ratio. Lack of cytotoxic activity in low density MLTC was not due to an impairment of cytotoxic precursors since cytotoxicity was rescued by adding exogenous interleukin-2 in experimental conditions in which no lymphokine-activated killer cells could develop relevant anti-CA-2 lysis. When low density MLTC were supplemented with either 800 R-irradiated cells or nonirradiated, negatively selected Lyt 1+ cells from the same immune mice, induction of a cytotoxic response against CA-2 occurred and interleukin-2 production became detectable. Additional studies indicated that spleen cells of CA-2-immune mice were also impaired in their ability to provide help to syngeneic thymocytes for the generation of cytotoxic T lymphocytes against C57BL/6J alloantigens. Dilution effect of helper cells due to immunization procedures was excluded since spleen cells of mice immunized against another BALB/c tumor, the YC8 lymphoma, or against DBA/2 minor histocompatibility antigens provided good help to thymocytes against the same alloantigens. These results indicate that tumor-immune animals may also have selective T helper defects in an important lymphoid organ like spleen.

This is a preview of subscription content, log in to check access.


  1. 1.

    Bellgrau D, Zoller M (1983) Cytotoxic T lymphocytes response to spontaneous tumors: immunogenicity dependent on the recognition of processed tumor antigens. J Immunol 130:2005

  2. 2.

    Berendt MJ, North RJ (1980) T-cell-mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69

  3. 3.

    Burger CJ, Elgert KD, Farrar WL (1984) Interleukin-2 (IL-2) activity during tumor growth: IL-2 production, kinetics, absorption of and responses to exogeneous IL-2. Cell Immunol 84:228

  4. 4.

    Cantor H, Boyse EA (1975) Functional subclasses of T lymphocytes bearing different Ly antigens. II. Cooperation between subclasses of Ly+ cells in the generation of killer activity. J Exp Med 141:1390

  5. 5.

    Carbone G, Colombo MP, Sensi ML, Cernuschi A, Parmiani G (1983) In vitro detection of cell-mediated immunity to chemically induced BALB/c fibrosarcomas. Int J Cancer 31:483

  6. 6.

    Forni G, Giovarelli M (1984) In vitro reeducated T helper cells from sarcoma-bearing mice inhibit sarcoma growth in vivo. J Immunol 132:527

  7. 7.

    Frost P, Prete P, Kerbel R (1982) Abrogation of the in vitro generation of the cytotoxic T-cell response to a murine tumor: the role of suppressor cells. Int J Cancer 30:211

  8. 8.

    Fujimoto S, Green MJ, Sehon AA (1976) Regulation of the immune response to tumor antigens. The nature of immunosuppressor cells in tumor bearing hosts. J Immunol 116:800

  9. 9.

    Fuyama S, Yamamoto H, Arai S (1985) Characterization of effector cells mediating antitumor activity in spleen cells of tumor-bearing mice. Cancer Res 45:4103

  10. 10.

    Gullberg M, Larsson EL (1982) Studies on the induction and effector function of Concanavalin A-induced suppressor cells that limit TCGF production. J Immunol 128:746

  11. 11.

    Giorgi JV, Warner NL (1983) Tumor immunity to murine plasma-cell tumors. VIII. Immunosuppression of the generation of cytotoxic T cells by murine plasma-cell tumor lines. Int J Cancer 32:629

  12. 12.

    Hellstrom KE, Hellstrom I (1974) Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol 18:209

  13. 13.

    Hewitt HB, Blacke ER, Walder AS (1976) A critique of the evidence for active host defense against cancer, based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer 33:241

  14. 14.

    Jenski LJ, Ledford T (1985) Murine leukemic cells inhibit IL-2 production by susceptible syngeneic splenocytes. J Immunol 135:3178

  15. 15.

    Kramer M, Koszinowski U (1982) T cell-specific suppressor factor(s) with regulatory influence on interleukin 2 production and function. J Immunol 128:784

  16. 16.

    Lee FH, Currie D, Hwang KM (1984) Analysis of the involvement of cells from donor and recipient mice in adoptive transfer of antitumor immunity. Cancer Res 44:5491

  17. 17.

    Nishimura T, Togashi Y, Goto M, Yagi H, Uchiyama Y, Hashimoto Y (1986) Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2. Cancer Immunol Immunother 21:12

  18. 18.

    Old LJ, Boyse EA, Clarke DA, Carswell EA (1966) Antigenic properties of chemically induced tumors. Annu Rev Microbiol 20:223

  19. 19.

    Pilarski LM (1977) A requirement for antigen-specific helper T cells in the generation of cytotoxic T cells from thymocyte precursors. J Exp Med 145:709

  20. 20.

    Plescia OJ, Grinwich K, Smith A, Sheridan J, Plescia AM (1977) In: Lucas DO (ed) Regulatory mechanisms in lymphocyte activation. Academic Press, New York

  21. 21.

    Rosenberg SA (1985) Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst 75:595

  22. 22.

    Ryser JE, Cerottini JC, Brunner KT (1978) Generation of cytolytic T lymphocytes in vitro. IX. Induction of secondary CTL responses in primary long term MLC by supernatants from secondary MLC. J Immunol 120:370

  23. 23.

    Sensi ML, Carbone G, Parmiani G (1980) Original H-2d and alien H-2k-like antigens of a BALB/c fibrosarcoma as defined by in vitro and in vivo studies of cell-mediated immunity. Eur J Immunol 10:671

  24. 24.

    Smith KA (1980) T cell growth factors. Immunol Rev 51:337

  25. 25.

    Stackpole C, Jacobson I (1978) Antigen modulation. In: Waters H (ed) The handbook of cancer immunology. Cellular escape from immune destruction, vol 2. Grand Publishing Inc., New York, pp 55

  26. 26.

    Susskind BM, Merluzzi VJ, Faanes RB, Palladino MA, Choi YS (1983) Regulatory mechanism of cytotoxic T lymphocytes development. J Immunol 130:527

  27. 27.

    Talmadge JE (1985) Immunoregulation and immunostimulation of murine lymphocytes by recombinant human interleukin-2. J Biol Response Mod 4:18

  28. 28.

    Ting CC, Rodrigues D (1982) Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression. J Natl Cancer Inst 69:867

  29. 29.

    Urban JL, Schreiber H (1984) Rescue of the tumor-specific immune response of aged mice in vitro. J Immunol 133:527

  30. 30.

    Zoller M (1985) Evaluation of in vivo and in vitro effectivity of immune defense against a spontaneously arising, nonlymphoid rat tumor. Cancer Immunol Immunother 19:189

Download references

Author information

Correspondence to Giorgio Parmiani.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Grazioli, L., Sensi, M. & Parmiani, G. Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma. Cancer Immunol Immunother 24, 237–243 (1987). https://doi.org/10.1007/BF00205636

Download citation


  • Spleen Cell
  • Fibrosarcoma
  • Peritoneal Exudate
  • Histocompatibility Antigen
  • Cytotoxic Response